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THE ALZHEIMER’S DISEASE SEQUENCING
PROJECT: STUDY DESIGN AND SAMPLE
SELECTION
Late-onset Alzheimer disease (LOAD) is the leading
cause of dementia worldwide, with substantial economic
and public health implications.1 LOAD is a neurodegen-
erative disease characterized by progressive dementia
typically manifesting in the seventh to ninth decades.
Neuropathological changes precede clinical symptoms
by 10–20 years, resulting in clinically asymptomatic
individuals carrying neuropathologic features of
LOAD.2 Much of the heritability of LOAD remains
unexplained, despite LOAD having a high heritability
(60%–80%) and despite the identification of the APOE
locus, a major genetic determinant for LOAD.3 Genetic
analyses have identified more than 25 other variants
associated with smaller individual effects on disease risk.4
To identify novel genetic variation influencing AD
risk and protection, the Alzheimer’s Disease Sequenc-
ing Project (ADSP) was implemented as a collabora-
tive effort of the National Institutes on Aging, the
National Human Genome Research Institute, and
the Alzheimer disease research community. Individ-
ual contributors include the Alzheimer’s Disease
Genetics Consortium, the Neurology Phenotype
Working Group of the Cohorts for Heart and Aging
Research in Genomic Epidemiology consortium,
and the Large Scale Sequencing and Analysis
Centers at Baylor University, the Broad Institute,
and Washington University.
Study design and sample selection were conducted
to address issues of phenotypic heterogeneity and max-
imize statistical power. The study design includes 2 pri-
mary phases: a whole-genome sequencing (WGS)
family-based study and a whole-exome sequencing
(WES) case-control study. The WGS study was de-
signed to target rarer variation through allelic segrega-
tion and linkage analyses in multiplex AD families.
The WES case-control study was designed to target
low-frequency coding variation in genes that contrib-
ute to AD risk or protection.
ADSP family study design. Approximately 1,400
multiplex LOAD families were reviewed for inclusion.
Families were required to have multiple members with
LOAD, genomic DNA, and available APOE genotypes.
Families meeting initial criteria were assigned a priority
rank based on number and age at onset of affected in-
dividuals, number of generations affected, and presence
of APOE e4 alleles. Priority was given to families heavily
loaded for AD ($4 affected members with DNA avail-
able) with minimal APOE e4 alleles. Cases met National
Institute of Neurological Diseases–Alzheimer’s
NINCDS-ADRDA (National Institute of Neurological
and Communicative Disorders and Stroke, and the
Alzheimer’s Disease and related Disorders Association;
now, Alzheimer’s Association) criteria for possible,
probable, or definite AD. Controls were free of clinical
AD on cognitive assessment. A detailed description of
the family design is in Appendix 1 at Neurology.org/ng.
In total, we selected 582 individuals (498 affected
and 84 unaffected) from 111 families for WGS to
identify genomic regions associated with increased
risk of LOAD. Selected individuals include 229 Euro-
pean ancestry and 353 Caribbean Hispanic (CH) in-
dividuals (table). The European ancestry families
included 2 large Dutch families from the Erasmus
Rucphen Family study.5 Most of these families were
recently analyzed for genetic linkage, an analysis that
will be used in the analysis of the sequence data.6,7 By
design, no e4/e4 individuals were selected for
sequencing, and we prioritized e3/e4 individuals with
earlier disease onset. Twenty-seven percent of families
had at least 1 case with autopsy confirmation.
ADSP case-control design. Over 30,000 samples
were considered for inclusion in the case-control
design. All cases met NINCDS-ADRDA criteria for
possible, probable, or definite AD, had documented
age at onset or age at death (for pathologically verified
cases), and APOE genotyping. All controls were at
least 60 years old and were free of dementia by direct,
documented cognitive assessment. Three primary
case-control selection strategies were evaluated, and
ultimately, a design was chosen that targeted cases
with minimal risk as predicted by known risk factors
(age, sex, and APOE) and targeted controls with the
least probability of conversion to AD by age 85 years.
The details and rationale of the case-control selection
process and the evaluation of alternate study designs
are described in detail in Appendix 2.
In total, we selected 5,096 cases and 4,965 con-
trols under the chosen design (table). We selected
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682 additional unrelated cases from additional mul-
tiplex families that had a strong family history for
LOAD. Because some of these 682 cases arose from
CH multiplex families, we included 171 cognitively
normal CH control samples in the WES.
The sequencing of the nearly 600 whole genomes
and 11,000 whole exomes has been completed; the
data sets are currently available to the research com-
munity through qualified access (dbGaP study
phs000572.v7.p4). This data set will be used to iden-
tify genetic factors influencing AD risk and protection
and will be a critical resource for the LOAD research
community.
Standard protocol approvals, registrations, and
patient consents. This study has the approval of the
institutional review boards of participating institu-
tions, and informed consent was obtained from all
patients.
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